NICE recommends ‘game changing’ histology independent cancer drug
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).
All NICE products on genomic biomarker-based cancer treatments. Includes any guidance.
We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Published guidance on this topic (2)
Reviews the clinical and cost-effectiveness of new treatments.
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).